Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지

Analysis of Palivizumab Prophylaxis in Patients with Acute Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus

Respiratory syncytial virus로 인한 급성 하기도 감염 입원 환자에서 Palivizumab 예방요법 유무에 따른 비교 분석

  • Min, Sung Ju (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Song, Jung Sook (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Choi, Jang Hwan (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Seon, Han Su (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Kang, Eun Kyeong (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Kim, Do Hyun (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Kim, Hee Sup (Department of Pediatrics, Dongguk University Ilsan Hospital)
  • 민성주 (동국대학교 일산병원 소아청소년과) ;
  • 송정숙 (동국대학교 일산병원 소아청소년과) ;
  • 최장환 (동국대학교 일산병원 소아청소년과) ;
  • 선한수 (동국대학교 일산병원 소아청소년과) ;
  • 강은경 (동국대학교 일산병원 소아청소년과) ;
  • 김도현 (동국대학교 일산병원 소아청소년과) ;
  • 김희섭 (동국대학교 일산병원 소아청소년과)
  • Received : 2011.06.11
  • Accepted : 2011.09.09
  • Published : 2011.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The aim of this study was to identify the clinical characteristics of lower respiratory tract infection due to respiratory syncytial virus (RSV) in young children and to provide information for an effective guideline for palivizumab administration in Korea. Methods : We reviewed medical charts of 167 patients under 3 years of age who were hospitalized in Dongguk University Ilsan Hospital for lower respiratory tract infection between January 2007 and February 2011. Diagnosis of the virus was made based on the multiplex real time polymerase chain reaction. Results : There were 113 patients who were infected by respiratory syncytial virus. 90 patients were term infants and 23 patients were preterm infants. No difference was shown between term and preterm infants except the days of admission which was 9.0${\pm}$6.0 days and 12.6${\pm}$21.0 days respectively. In the preterm group their mean age at the time of admission was 5.21${\pm}$4.9 months and the mean gestational age was 33.1${\pm}$4.3 weeks, and the mean birth weight was 2,152${\pm}$950 g. Only 4 patients were born under 28 weeks gestational age and were candidates for palivizumab administration. Conclusion : Most of the patients with severe RSV lower respiratory tract infection were term or near term infants who were not candidates for palivizumab prophylaxis. A nationwide study is needed to make a new risk stratified guideline for RSV prophylaxis for our country.

목 적: Respiratory syncytial virus (RSV)에 의한 급성 하기도 감염은 소아기에 입원을 요하는 중요한 질환이다. 우리나라에서는 현재 미숙아와 후기미숙아의 출생률과 생존률이 증가하고 있으며, palivizumab ($Synagis^{(R)}$) 예방요법을 시행하고 있으나 아직 경제효과에 대한 연구가 없는 실정이다. 이에 저자들은 RSV로 인한 하기도 감염으로 입원한 미숙아들의 인구학적, 임상적 특성을 알아보고 우리나라에 적절한 예방요법 대상을 정하는데 도움이 되는 정보를 제공하고자 하였다. 방 법: 2007년 1월부터 2011년 2월까지 동국대학교 일산병원에 입원한 3세 미만의 급성 하기도 감염 환자중 multiplex RT-PCR을 통해 원인 바이러스를 밝힌 167명의 의무기록을 후향적으로 조사하였다. 결 과: 167명 중 RSV 감염으로 밝혀진 환자는 총 113명이었으며, 만삭아가 90명, 미숙아가 23명이었다. 이들의 평균 입원기간은 만삭아군이 9.0일, 미숙아군이 12.6일로 통계학적인 차이를 보였으며 이외 입원당시 나이, 발열 및 호흡기 증상, 혈액소견등은 유의한 차이를 보이지 않았다. RSV 감염으로 입원한 미숙아 22명을 조사하였을때(다른 질병과의 동반감염이 있었던 한 명 제외), 28주 미만이 4명, 28주 이상 32주 미만이 2명, 32주 이상이 16명(72.7%)으로 대부분이 palivizumab 예방요법의 대상이 아닌 미숙아들이었다. 이들 중 3명은 중환자실에서의 치료를 받았고 한 명만 28주미만의 환아로 palivizumab 투여를 받았으며 나머지 두 명은 32주 이상의 환아들로 기관지폐이형성 등 다른 위험요소가 없어 palivizumab을 투여 받지 않았다. 중환자실에서 치료받은 미숙아군과 만삭아군에서도 임상양상과 혈액학적 소견은 모두 유의한 차이를 보이지 않았다. 결 론: RSV에 의한 급성 하기도 감염으로 입원하는 환자들은 대부분 만삭아이거나 기관지폐이형성증과 같은 위험요인이 없는, palivizumab 투여 대상이 아닌 미숙아들이었다. 따라서 우리나라에서도 기관지폐이형성증 이외의 위험요인을 평가하고 더욱 최적의 시기에 pali-vizumab을 투여 하는 우리나라만의 예방요법지침이 하루속히 필요하다고 생각된다.

Keywords

References

  1. Park JS. Acute viral lower respiratory tract infections in children. Korean Journal of Pediatrics 2009;52:269-76. https://doi.org/10.3345/kjp.2009.52.3.269
  2. Jung BS, Cho B, Kim HH, Lee JS. A clinical study of respiratory tract infection. Pediatr Allergy Respir Dis (Korea). 1996;6:60-3.
  3. Elliot AJ, Fleming DM. Viral infections and acute otitis media in young children. Clin Infect Dis 2008;47:146-7.
  4. Williams JV. The clinical presentation and outcomes of children infected with newly identified respiratory tract viruses. Infect Dis Clin North Am. 2005;19:569-84. https://doi.org/10.1016/j.idc.2005.05.009
  5. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004;5:119-26. https://doi.org/10.1016/S1526-0542(04)90023-1
  6. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virust . Pediatr InfecDis J 2003;21-32.
  7. Hahn WH, Chang JY, Bae CW. Birth statistics and mortality rates for neonatal intensive care units in Korea during 2007: collective results from 57 hospitals. J Korean Soc Neonatol 2009;16:36-46.
  8. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
  9. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992;45:180-91.
  10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7. https://doi.org/10.1542/peds.102.3.531
  11. Prais D, Schonfeld T, Amir J. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 2003;112:548-52. https://doi.org/10.1542/peds.112.3.548
  12. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006;42:253-8. https://doi.org/10.1111/j.1440-1754.2006.00850.x
  13. Farina D, Rodriguez SP, Bauer G, Novali L, Bouzas L, Gonzalez H, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21:287-91. https://doi.org/10.1097/00006454-200204000-00006
  14. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15. https://doi.org/10.1007/s10198-009-0206-x
  15. Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-60. https://doi.org/10.1016/j.clinthera.2008.03.014
  16. Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadianbased analysis. Curr Med Res Opin 2008;24:3223-37. https://doi.org/10.1185/03007990802484234
  17. Denny FW, Clyde WA, Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 1986;108:635-46. https://doi.org/10.1016/S0022-3476(86)81034-4
  18. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28. https://doi.org/10.1056/NEJM200106213442507
  19. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806-14. https://doi.org/10.1097/01.inf.0000137568.71589.bd
  20. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002;96:1-7. https://doi.org/10.1053/rmed.2001.1207
  21. Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, et al. Epidemiology of respiratory syncytial virus in children ${\leq}$2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol 2010;2:221-7.
  22. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 2011;17:254-63. https://doi.org/10.1007/s10156-010-0121-1
  23. Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009;10:143-7. https://doi.org/10.1016/j.prrv.2009.06.002
  24. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9. https://doi.org/10.1542/peds.99.1.93
  25. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003;22:46-54.
  26. American academy of pediatrics committee on infectious diseases and committee of fetus and newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSVIGIV. Pediatrics 1998;102:1211-6. https://doi.org/10.1542/peds.102.5.1211
  27. Resch B, Paes B. Are late preterm infants as susceptible to RSV infection as full term infants? Early Hum Dev 2011;87:47-9. https://doi.org/10.1016/j.earlhumdev.2011.01.010
  28. Lanari M, Silvestri M, Rossi GA. Palivizumab prophylaxis in 'late preterm' newborns. J Matern Fetal Neonatal Med 2010;23:53-5. https://doi.org/10.3109/14767058.2010.506757
  29. Figueras Aloy J, Quero J, Domenech E, Lopez Herrera MC, Izquierdo I, Losada A, et al. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63:357-62. https://doi.org/10.1157/13079818